Results 281 to 290 of about 1,472,669 (399)

Polymyxin B Induced Acute Diaphragmatic Paralysis: A Case Report Based on Therapeutic Drug Monitoring. [PDF]

Pharmacol Res Perspect
Zhang Y, Tang X, Li Y, Su X, Zhong X, Huang Z.   +5 more
europepmc   +1 more source

Effectiveness and safety of baricitinib for juvenile idiopathic arthritis associated uveitis or chronic anterior antinuclear antibody positive uveitis

Arthritis Care &Research, Accepted Article.
Objectives Evaluate the efficacy and safety of baricitinib in paediatric patients with active JIA‐U or chronic anterior ANA‐positive uveitis, who had an inadequate response to MTX or bDMARDs. Methods JUVE‐BRIGHT was an open‐label, active‐controlled, Phase‐3 multicentre trial which utilized a novel design, including 1:1 randomization to an active ...
Athimalaipet V. Ramanan, Catherine M. Guly, Gabriele Simonini, Stuart Keller, Priyanka Sen, Thorsten Holzkaemper, Joana Araújo, Pierre Quartier   +7 more
wiley   +1 more source

Developed HPTLC-densitometric for therapeutic drug monitoring

Archives of Pharmacy Practice, 2012
I Made Agus Gelgel Wirasuta, Rai Gunawan, Ni Made Pitri Susanti, Ni Putu Linda Laksmiani   +3 more
doaj  

Comparative evaluation of five tacrolimus assays in transplant recipients: implications for optimizing therapeutic drug monitoring. [PDF]

Front Transplant
SahBandar IN, Zhao Z, Racine-Brzostek SE, Rai AJ, Cid M, Cushing MM, Lindeman N, Muthukumar T, Yang HS.   +8 more
europepmc   +1 more source

Therapeutic drug monitoring.

The Practitioner, 1987
  +6 more sources

Clinical Outcomes of Patients Within the Rheumatoid Arthritis Care Pathway Cohort at a Tertiary Care Integrated Delivery Network: A Comparison to Usual Care

Arthritis Care &Research, EarlyView.
Objective We aimed to compare clinical outcomes between patients in the Allegheny Health Network rheumatoid arthritis (RA) care pathway and patients receiving usual care. Methods The care pathway initiative implements guideline‐based best practice alongside multidisciplinary team‐based care.
Tarun Sharma, Tyson S. Barrett, Teigan Dwyer, Nancy Campbell, Jessica Heintzinger, Ellen Kraemer, Adam Dore, Susan Manzi   +7 more
wiley   +1 more source

Therapeutic Drug Monitoring of Psychotropic Drugs in Inpatient Psychiatry: Local Practice and Improvement. [PDF]

Psychiatry Clin Psychopharmacol
Pfeifer P, Mathys B, Alan EM, Bracht T, Choinowski S, Adorjan K, Klöppel S.   +6 more
europepmc   +1 more source

Serum Soluble Mediator Signatures of Lupus Nephritis: Histologic Features and Response to Treatment

Arthritis Care &Research, EarlyView.
Objective Lupus nephritis (LN) management remains challenging, and novel noninvasive biomarkers are needed. This study quantified serum soluble mediators in the Accelerating Medicines Partnership (AMP) LN cohort to identify biomarkers of histologic features and treatment response.
Andrea Fava, Catriona A. Wagner, Carla J. Guthridge, Susan Macwana, Wade DeJager, Melissa E. Munroe, Peter Izmirly, H. Michael Belmont, Betty Diamond, Anne Davidson, Paul J. Utz, Michael H. Weisman, Philip M. Carlucci, Maria Dall'Era, Kenneth Kalunian, Chaim Putterman, Jennifer Anolik, Jennifer L. Barnas, David Wofsy, Diane Kamen, Richard A. Furie, Deepak A. Rao, the Accelerating Medicines Partnership Rheumatoid Arthritis and Systemic Lupus Erythematosus Network, Chun‐Hao Lee, Derek Fine, Manny Monroy‐Trujillo, Ummara Shah, Mariko Ishimori, Robert M. Clancy, Michael Belmont, Ming Wu, Nicole Bornkamp, Evan Der, Beatrice Goilav, Nicole Jordan, Daniel Schwartz, James Pullman, David Wofsy, Dawn Smilek, Patti Tosta, Matthias Kretzler, Celine C. Berthier, E. Steve Woodle, Dave Hildeman, Michael Brenner, Michelle Petri, Joel M. Guthridge, Jill Buyon, Judith A. James   +48 more
wiley   +1 more source

Quality Assessment of Therapeutic Drug Monitoring Assays of Therapeutic Antibodies Across Europe: An Update. [PDF]

Basic Clin Pharmacol Toxicol
Bluett J, Rumano M, Martínez Becerra MJ, Loeff F, Itik M, Ternant D, Desvignes C, Mulleman D, Skrede S.   +8 more
europepmc   +1 more source